Authors:
Address: Prometheus Laboratories Inc., San Diego, CA 92121, USA. jnicandro@prometheuslabs.com
Journal:

Publication:

abstract

OBJECTIVES:

This article evaluates the characteristics and treatment patterns of female patients with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who were treated with alosetron under a risk management program.

METHODS:

Patients prescribed alosetron (2002-2009) and who voluntarily enrolled in the follow-up study were evaluated. Questionnaires were administered at baseline, Wk 5, Wk 10, and quarterly thereafter for ≤1 year. Subgroup analyses were conducted in female patients with IBS-D ≥6 months, stratified by IBS-D severity criteria met (1-3) from the alosetron prescribing information (treatment recommended in female patients meeting ≥1 severity criterion). The voluntary and observational nature of the study are potential limitations, such that eligible patients in the clinical practice setting may have had more severe IBS-D, possibly representing a more motivated and homogeneous subpopulation of patients than the broader IBS-D population.

RESULTS:

A total of 7841 patients enrolled in the study; 92.4% were adult females; 79.4% (n = 6229) met label criteria. Mean follow-up time was ∼10.3 months; 50.3% completed 1 year. Of the 6229 female patients, 76.9% met 3/3 severity criteria; 21.5% met 2/3 severity criteria; 1.4% met 1/3 severity criteria. The most common complaint was restriction of daily activities, followed by accidents/fecal incontinence, and stomach cramps/bloating. One-year treatment continuation was ≥64% across IBS-D severity groups.

CONCLUSIONS:

One-year treatment continuation with alosetron was high, irrespective of the number of IBS-D severity criteria met. Restriction of daily activities was the primary indicator of disease severity. These findings demonstrate that alosetron continues to be safely and effectively used under the risk management program, and appears to provide long-term benefit in appropriate patients with IBS-D.

Related Articles
Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Clin Ther. 2008
Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R, Nikfar S, Abdollahi M. Clin Ther. 2008 May; 30(5):884-901.
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Am J Gastroenterol. 2007
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG. Am J Gastroenterol. 2007 Aug; 102(8):1709-19. Epub 2007 May 17.
Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.
Therap Adv Gastroenterol. 2010
Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.
Lucak SL. Therap Adv Gastroenterol. 2010 May; 3(3):165-72.
Review Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Curr Med Res Opin. 2011
Review Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S. Curr Med Res Opin. 2011 Mar; 27(3):503-12. Epub 2011 Jan 6.
Review The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Drug Saf. 2011
Review The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH. Drug Saf. 2011 Jul 1; 34(7):545-65.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster